Dyslipidemia Epidemiology Analysis and Forecast to 2032

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3995
Buy Report Download FREE Resources

Published: May 31, 2023 Report Code: GDHCER307-23-ST

Select Item

Dyslipidemia Epidemiology Analysis Report Overview

In the 7MM, there were 287,608,383 diagnosed prevalent cases of Dyslipidemia in 2022. The cases are expected to achieve an AGR of less than 1% during the period 2022-2032. The following are some of the key highlights of the Dyslipidemia epidemiology analysis report:

  • Of the 7MM, the US is expected to have the highest number of total prevalent cases, and Italy will have the lowest number of total prevalent cases of dyslipidemia in 2032.
  • In France, Germany, Italy, Spain, and the UK, the peak total prevalent cases of dyslipidemia by age occurred in ages 50–59 years.
  • In the US, the number of cases of Dyslipidemia in men was much higher than in other markets

Dyslipidemia Market Outlook, 2022-2032 (Diagnosed Prevalent Cases)

Dyslipidemia Market Outlook, 2022-2032 (Diagnosed Prevalent Cases)

Buy the Report for More Insights into the Dyslipidemia Market Forecast, Download a Free Report Sample

The Dyslipidemia market research report provides an overview of the risk factors, comorbidities, and global and historical trends for dyslipidemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of dyslipidemia segmented by age and sex in these markets. Additionally, the report provides the total prevalent cases of increased LDL-C, high TGs, very high TGs, and low HDL-C segmented by age and sex in these markets. The report also provides a 10-year epidemiological forecast of the total prevalent cases of familial hypercholesterolemia (FH) in these markets.

  Market Size (2022)  287,608,383 cases
  AGR (2022 – 2031)  <1%
Key Age Segments ·       20-29 years

·       30-39 years

·       40-49 years

·       50-59 years

·       60-69 years

·       70-79 years

·       80 years and older
Key Sex Segments ·       Men

·       Women
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

 

Dyslipidemia Market Segmentation by Age

Based on age, the Dyslipidemia market can be segmented into 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older. In 2022, for the 7MM combined, adults ages 50–59 years contributed the highest proportion of the total prevalent cases of dyslipidemia with more than 19% cases.

Dyslipidemia Market Analysis, by Age, 2022 (%)

Dyslipidemia Market Analysis, by Age, 2022 (%)

Buy the Full Report for More Age Insights Into the Dyslipidemia Market, Download a Free Report Sample

Dyslipidemia Market Segmentation by Sex

Based on sex, the Dyslipidemia market can be segmented into men and women. In the 7MM in 2022, most total prevalent cases of dyslipidemia occurred in men with more than 58% cases.

Dyslipidemia Market Analysis, by Sex, 2022 (%)

Dyslipidemia Market Analysis, by Sex, 2022 (%)

Buy the Full Report for More Sex Insights into the Dyslipidemia Market, Download a Free Report Sample

Segments Covered in the Report

Dyslipidemia Market Age Segments Outlook (Diagnosed Prevalent Cases, 2022-2032)

  • 20-29 years
  • 30-39 years
  • 40-49 years
  • 50-59 years
  • 60-69 years
  • 70-79 years
  • 80 years and older

Dyslipidemia Market Sex Segments Outlook (Diagnosed Prevalent Cases, 2022-2032)

  • Men
  • Women

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for dyslipidemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of dyslipidemia segmented by age (20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older) and sex in these markets. Additionally, the report provides the total prevalent cases of increased LDL-C, high TGs, very high TGs, and low HDL-C segmented by age (20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older) and sex in these markets. The report also provides a 10-year epidemiological forecast of the total prevalent cases of familial hypercholesterolemia (FH) in these markets.

Reasons to Buy

The Dyslipidemia epidemiology series will allow you to –

  • Develop business strategies by understanding the trends shaping and driving the global Dyslipidemia market.

  • Quantify patient populations in the global Dyslipidemia market to improve product design, pricing, and launch plans.

  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for Dyslipidemia therapeutics in each of the markets covered.

Table of Contents

  • 1. Dyslipidemia: Executive Summary

    • 1.1. Catalyst

    • 1.2. Related Reports

    • 1.3. Upcoming Reports

  • 2. Epidemiology

    • 2.1. Disease background

    • 2.2. Risk factors and comorbidities

    • 2.3. Global and historical trends

    • 2.4. 7MM forecast methodology

      • 2.4.1. Sources

      • 2.4.2. Forecast assumptions and methods

      • 2.4.3. Forecast assumptions and methods: total prevalent cases of dyslipidemia

      • 2.4.4. Forecast assumptions and methods: diagnosed prevalent cases of dyslipidemia

      • 2.4.5. Forecast assumptions and methods: total prevalent cases of familial hypercholesterolemia

      • 2.4.6. Forecast assumptions and methods: total prevalent cases of increased low-density lipoprotein cholesterol

      • 2.4.7. Forecast assumptions and methods: total prevalent cases of high triglycerides

      • 2.4.8. Forecast assumptions and methods: total prevalent cases of very high triglycerides

      • 2.4.9. Forecast assumptions and methods: total prevalent cases of low high-density lipoprotein cholesterol

      • 2.4.10. Forecast assumptions and methods: total prevalent cases of mixed dyslipidemia

    • 2.5. Epidemiological forecast for dyslipidemia (2022–32)

      • 2.5.1. Total prevalent cases of dyslipidemia

      • 2.5.2. Age-specific total prevalent cases of dyslipidemia

      • 2.5.3. Sex-specific total prevalent cases of dyslipidemia

      • 2.5.4. Diagnosed prevalent cases of dyslipidemia

      • 2.5.5. Age-specific diagnosed prevalent cases of dyslipidemia

      • 2.5.6. Sex-specific diagnosed prevalent cases of dyslipidemia

      • 2.5.7. Total prevalent cases of familial hypercholesterolemia

      • 2.5.8. Total prevalent cases of increased low-density lipoprotein cholesterol

      • 2.5.9. Age-specific total prevalent cases of increased low-density lipoprotein cholesterol

      • 2.5.10. Sex-specific total prevalent cases of increased low-density lipoprotein cholesterol

      • 2.5.11. Total prevalent cases of high triglycerides

      • 2.5.12. Age-specific total prevalent cases of high triglycerides

      • 2.5.13. Sex-specific total prevalent cases of high triglycerides

      • 2.5.14. Total prevalent cases of very high triglycerides

      • 2.5.15. Age-specific total prevalent cases of very high triglycerides

      • 2.5.16. Sex-specific total prevalent cases of very high triglycerides

      • 2.5.17. Total prevalent cases of low high-density lipoprotein

      • 2.5.18. Age-specific total prevalent cases of low high-density lipoprotein cholesterol

      • 2.5.19. Sex-specific total prevalent cases of low high-density lipoprotein cholesterol

      • 2.5.20. Total prevalent cases of mixed dyslipidemia

    • 2.6. Discussion

      • 2.6.1. Epidemiological forecast insight

      • 2.6.2. COVID-19 impact

      • 2.6.3. Limitations of the analysis

      • 2.6.4. Strengths of the analysis

  • 3. Appendix

    • 3.1. Bibliography

    • 3.2. About the Authors

    • 3.3. Epidemiologist

    • 3.4. Reviewers

    • 3.5. Vice President of Disease Analysis and Intelligence

    • 3.6. Global Head and EVP of Healthcare Operations and Strategy

  • 4. Contact Us

Table

Table 1: Summary of newly added data types

Table 2: Summary of updated data types

Table 3: Risk factors and comorbidities for dyslipidemia

Table 4: Total prevalent cases of increased LDL-C, both sexes, N, ages ≥20 years, 2022-2032

Table 5: Total prevalent cases of high TGs, both sexes, N, ages ≥20 years, 2022-2032

Table 6: Total prevalent cases of very high TGs, both sexes, N, ages ≥20 years, 2022-2032

Table 7: Total prevalent cases of low HDL-C, both sexes, N, ages ≥20 years, 2022-2032

Figures

Figure 1: 7MM, total prevalent cases of dyslipidemia, both sexes, N, ages ≥20 years, 2022 and 2032

Figure 2: 7MM, diagnosed prevalent cases of dyslipidemia, both sexes, N, ages ≥20 years, 2022 and 2032

Figure 3: 7MM, total prevalence of dyslipidemia, men and women, %, ages ≥20 years, 2022

Figure 4: 7MM, diagnosed prevalence of dyslipidemia, men and women, %, ages ≥20 years, 2022

Figure 5: 7MM, sources used to forecast the diagnosed prevalent cases of dyslipidemia

Figure 6: 7MM, sources used and not used to forecast the total prevalent cases of high LDL-C

Figure 7: 7MM, sources used and not used to forecast the total prevalent cases of high TGs and very high TGs

Figure 8: 7MM, sources used and not used to forecast the total prevalent cases of low HDL-C

Figure 9: 7MM, sources used and not used to forecast the total prevalent cases of FH

Figure 10: 7MM, sources used to forecast the total prevalent cases of mixed dyslipidemia

Figure 11: 7MM, total prevalent cases of dyslipidemia, N, both sexes, ages ≥20 years, 2022

Figure 12: 7MM, total prevalent cases of dyslipidemia by age, N, both sexes, 2022

Figure 13: 7MM, total prevalent cases of dyslipidemia by sex, N, ages ≥20 years, 2022

Figure 14: 7MM, diagnosed prevalent cases of dyslipidemia, N, both sexes, ages ≥20 years, 2022

Figure 15: 7MM, diagnosed prevalent cases of dyslipidemia by age, N, both sexes, 2022

Figure 16: 7MM, diagnosed prevalent cases of dyslipidemia by sex, N, ages ≥20 years, 2022

Figure 17: 7MM, total prevalent cases of FH, N, both sexes, ages ≥20 years, 2022

Figure 18: 7MM, total prevalent cases of increased LDL-C by age, N, both sexes, 2022

Figure 19: 7MM, total prevalent cases of increased LDL-C by sex, N, ages ≥20 years, 2022

Figure 20: 7MM, total prevalent cases of high TGs by age, N, both sexes, 2022

Figure 21: 7MM, total prevalent cases of high TGs by sex, N, ages ≥20 years, 2022

Figure 22: 7MM, total prevalent cases of very high TGs by age, N, both sexes, 2022

Figure 23: 7MM, total prevalent cases of very high TGs by sex, N, ages ≥20 years, 2022

Figure 24: 7MM, total prevalent cases of low HDL-C by age, N, both sexes, 2022

Figure 25: 7MM, total prevalent cases of low HDL-C by sex, N, ages ≥20 years, 2022

Figure 26: 7MM, total prevalent cases of mixed dyslipidemia, N, both sexes, ages ≥20 years, 2022

Frequently asked questions

Dyslipidemia Epidemiology Analysis and Forecast to 2032 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

Most Popular
$7,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Dyslipidemia Epidemiology Analysis and Forecast to 2032 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Dyslipidemia reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Dyslipidemia Epidemiology Analysis and Forecast to 2032 in real time.

  • Access a live Dyslipidemia Epidemiology Analysis and Forecast to 2032 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more